Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249301
Status:
TERMINATED
Last Update Posted:
2008-04-01
First Post:
2005-11-04
Brief Title:
A Study of MLN8054 in Patients With Advanced Solid Tumors
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
An Open-Label Dose Escalation Phase 1 Study of MLN8054 a Novel Aurora A Kinase Inhibitor in Patients With Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine 1 The side effects or toxicities of MLN80542 The highest dose where side effects or toxicities are not too severe 3 How MLN8054 is absorbed into the general blood circulation and eliminated from the body and 4 The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None